Efficacy of cabozantinib in the 1st line therapy of progressing multiple primary metachronous renal cell carcinomas: clinical observation

In 2023 in Russia, renal cell carcinoma (RCC) was the 7th most common cancer among men and the 12th among women. According to the data of the national cancer register, in approximately 18 % of patients, RCC is diagnosed at a late  stage and with distant metastases. Another large group (between 20 and 40 %) are patients who underwent radical surgical treatment at a localized stage but whose disease progressed into metastatic stage. Frequency of bilateral tumor lesions in both kidneys is 2 to 6 % of all RCC cases.

In the presented rare clinical observation of a patient with bilateral metachronous metastatic RCC, late metachronous tumor in the contralateral kidney 13 years after diagnosis of the primary tumor, different histological types of the tumors (clear cell and non-clear cell papillary RCC), efficacy of cabozantinib therapy in combination with immunotherapeutic drug nivolumab and as monotherapy is demonstrated. Objective response to treatment was achieved. The patient had intolerable immune-related toxicity – grade III adrenal gland failure – which required nivolumab cessation. Continued therapy with cabozantinib demonstrated satisfactory tolerability with controlled adverse events. Overall duration of response (disease control) to cabozantinib therapy is currently 24 months.

1. Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 275 p. (In Russ.).

2. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024. 262 p. (In Russ.).

3. Doppalapudi S.K., Leopold Z.R., Thaper A. et al. Clearing up clear cell: clarifying the immuno-oncology treatment landscape for metastatic clear cell RCC. Cancers (Basel) 2021;13(16):4140. DOI: 10.3390/cancers13164140

4. Bruckschen F., Gerharz C.D., Sagir A. Renal cell carcinoma with unusual metachronous metastasis up to 22 years after nephrectomy: two case reports. J Med Case Rep 2021;15(1):490. DOI: 10.1186/s13256-021-03098-5

5. Petrov L.O., Izmailov A.A., Ustimenko A.V. et al. Late progression of renal cell carcinoma after 32 years: clinical case. Onkourologiya = Cancer Urology 2024;20(2):110–5. (In Russ.). DOI: 10.17650/1726-9776-2024-20-2-110-115

6. Kel’n A.A., Lykov A.V., Kupchin A.V. Bilateral renal cell carcinoma. Tyumenskiy meditsinskiy zhurnal = Tyumen Medical Journal 2015;17(1):46–8. (In Russ.).

7. Davydov M.I., Matveev V.B. Surgical treatment of regional and metastatic renal cancer. Moscow: Izdatelskaya gruppa RONTS im. N.N. Blokhina RAMN, 2002. (In Russ.).

8. Moch H., Amin M.B., Berney D.M. et al. The 2022 World Health Organization Classification of Tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 2022;82(5):458–68. DOI: 10.1016/j.eururo.2022.06.016

9. Motzer R.J., Hutson T.E., Tomczak P. et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115–24. DOI: 10.1056/NEJMoa065044

10. Sternberg C.N., Davis I.D., Mardiak J. et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28(6):1061–8. DOI: 10.1200/JCO.2009.23.9764

11. Choueiri T.K., Halabi S., Sanford B.L. et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2016;35(6):591–7. DOI: 10.1200/JCO.2016.70.7398

12. Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378(14):1277–90. DOI: 10.1056/NEJMoa1712126

13. Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380:1116–27. DOI: 10.1056/NEJMoa1816714

14. Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI: 10.1056/NEJMoa1816047

15. Choueiri T.K., Eto M., Motzer R.J. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023;24(3):228–38. DOI: 10.1016/S1470-2045(23)00049-9

16. Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384:829–41. DOI: 10.1056/NEJMoa2026982

17. Heng D.Y., Xie W., Regan M.M. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27(34):5794–9. DOI: 10.1200/JCO.2008.21.4809

18. Wilson N.R., Acikgoz Y., Hasanov E. Advances in non-clear cell renal cell carcinoma management: from heterogeneous biology to treatment options. Int J Cancer 2024;154(6):947–61. DOI: 10.1002/ijc.34756

19. Yakes F.M., Chen J., Tan J. et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298–308. DOI: 10.1158/1535-7163.MCT-11-0264

20. Peltola K.J., Penttila P., Rautiola J. et al. Correlation of c-Met expression and outcome in patients with renal cell carcinoma treated with sunitinib. Clin Genitourin Cancer 2017;15(4):487–94. DOI: 10.1016/j.clgc.2017.01.021

21. Pal S.K., Tangen C., Thompson I.M. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, openlabel, phase 2 trial. Lancet 2021;397(10275):695–703. DOI: 10.1016/S0140-6736(21)00152-5